Utrecht, Netherlands
Utrecht, Netherlands

Time filter

Source Type

Short Course to Highlight Intracellular Cytokine Detection Assay in Adoptive Cell Therapy Trials and Poster to Highlight Metaproteomic Analysis of Gut Microbiome in Enfants Caprion Biosciences Inc. announced today that Dr. Yoav Peretz, Scientific Director of ImmuneCarta will lead a short course on novel techniques in development of Intracellular cytokine detection assays in adoptive cell therapy trials at the annual Molecular Medicine Triconference held in San Francisco, CA.  The course will focus on providing guidance on detection, persistence, and phenotypic characterization of pentamer CD8+ T cells in adoptive cell immunotherapy trials. Caprion will also have a poster presentation which features an exploratory discovery study on metaproteomic analysis of infant fecal microbiome.  The goal of the study was to extract gut microbiome taxonomy and functional data in a population of infant fecal samples. The results demonstrate a proteomics approach provides functional changes and responses with significantly greater coverage of bacterial genera than the pyrosequencing approach. Pathway analysis also underlines the differences between individual microbiomes and provides insights into their functional responses to diet, disease and therapy. Short Course: Development and Deployment of an Intracellular Cytokine Detection Assay in Adoptive Cell Therapy Trials   SC24 "Flow Cytometry and Phenotypic Cell Analysis in Immuno-Oncology" Speaker: Yoav Peretz, PhD, Scientific Director, ImmuneCarta Monday, Feb 20th, 10:10am Poster presentation at the conference "Metaproteomic Analysis of the Infant Fecal Microbiome" Laetitia Cortes[1], Aude Tartière[1], Julie Piquenot[1], Sebastian Tims[2], Joost W. Gouw[2], Jan Knol[2],[3], Harm Wopereis[2],[3] and Daniel Chelsky[1] [1]Caprion Biosciences Inc, Montreal, Canada; [2]Nutricia Research, Utrecht, the Netherlands; [3]Wageningen University, Laboratory of Microbiology, Wageningen, the Netherlands About Caprion Biosciences, Inc. Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP. For more information, please visit http://www.caprion.com.


Kurzlehrgang mit Fokus auf Assay zum Nachweis von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar Wie Caprion Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz, Scientific Director bei ImmuneCarta, einen Kurzlehrgang zu neuartigen Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der jährlich stattfindenden Molecular Medicine Triconference in San Francisco (Kalifornien) leiten.  Der Kurs konzentriert sich auf die Bereitstellung von Leitlinien für Nachweis, Persistenz und phänotypische Charakterisierung von Pentamer CD8+ T-Zellen bei adoptiven zellulären Immuntherapie-Studien. Caprion wird außerdem ein Poster zu einer explorativen Studie für die Ausforschung einer metaproteomischen Analyse des fäkalen Mikrobioms bei Säuglingen präsentieren.  Ziel der Studie war die Erstellung einer Taxonomie zum Darm-Mikrobiom und die Erhebung von Funktionsdaten aus Fäkalproben in einer Säuglingspopulation. Die Ergebnisse belegen, dass der proteomische Ansatz funktionelle Änderungen und Reaktionen mit deutlich größerer Abdeckung von Bakterien-Gattungen als eine Herangehensweise über Pyrosequenzierung liefert. Die Signalweganalyse arbeitet auch die Unterschiede zwischen individuellen Mikrobiomen heraus und bietet Einblicke in ihre funktionellen Reaktionen hinsichtlich Ernährung, Erkrankung und Therapie. Kurzlehrgang: Development and Deployment of an Intracellular Cytokine Detection Assay in Adoptive Cell Therapy Trials (Entwicklung und Einsatz eines Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien)   SC24 "Flow Cytometry and Phenotypic Cell Analysis in Immuno-Oncology" ("Durchflusszytometrie und phänotypische Zellanalyse in der Immunonkologie") Referent: Yoav Peretz, PhD, Scientific Director, ImmuneCarta Montag, 20. Februar, 10:10 Uhr Poster-Präsentation im Rahmen der Konferenz "Metaproteomic Analysis of the Infant Fecal Microbiome" ("Metaproteomische Analyse des fäkalen Mikrobioms bei Säuglingen") Laetitia Cortes[1], Aude Tartière[1], Julie Piquenot[1], Sebastian Tims[2], Joost W. Gouw[2], Jan Knol[2],[3], Harm Wopereis[2],[3] und Daniel Chelsky[1] [1]Caprion Biosciences Inc, Montreal, Canada; [2]Nutricia Research, Utrecht, Niederlande; [3]Universität Wageningen, Labor für Mikrobiologie, Wageningen, Niederlande Informationen zu Caprion Biosciences, Inc. Caprion stellt als führender Anbieter Proteomik und Immunüberwachungsdienste für die Pharma- und Biotechnologiebranche bereit. Caprions Geschäftsbereich ImmuneCarta® widmet sich der Immunüberwachung und liefert proprietäre multiparametrische Durchflusszytometrie für funktionale Analysen des angeborenen und erworbenen Immunsystems. Caprions Proteomik-Division, ProteoCarta™, bietet proprietäre gelfreie, markierungsfreie Massenspektrometrie (MS), die der umfassenden, quantitativen und robusten Vergleichsmessung von Proteinen in umfangreichen biologischen Probensets für die Entdeckung und Validierung von Proteinbiomarkern dient. Das in Montreal (Kanada) und Belgien ansässige Caprion stellt seit mehr als 15 Jahren großangelegte Proteomik- und Immunmonitoring-Dienste für mehr als 50 große Pharma- und Biotech-Kunden bereit. Caprion ist ein Privatunternehmen, das sich im Mehrheitsbesitz von Global Healthcare Opportunities bzw. GHO Capital Partners LLP befindet. Weitere Informationen finden Sie unter http://www.caprion.com.


Le cours de courte durée portera sur l'analyse de détection de cytokine intracellulaire dans des essais de thérapie cellulaire adoptive et une affiche présentera l'analyse métaprotéomique du microbiome intestinal chez le nourrisson Caprion Biosciences Inc. a annoncé aujourd'hui que le Dr. Yoav Peretz, directeur scientifique d'ImmuneCarta, allait encadrer un cours de courte durée sur de nouvelles techniques dans le développement d'essais de détection de cytokine intracellulaire dans des essais de thérapie cellulaire adoptive, dans le cadre de la tri-conférence de médecine moléculaire annuelle qui se tient à San Francisco, en Californie.  Le cours a pour objectif de fournir de conseils sur la détection, la persistance et la caractérisation phénotypique des cellules T CD8+ pentamères dans des essais d'immunothérapie cellulaire adoptive. Caprion présentera également une affiche illustrant une étude de découverte exploratoire sur l'analyse métaprotéomique du microbiome fécal du nourrisson.  L'objectif de l'étude était d'extraire la taxonomie du microbiome intestinal et des données fonctionnelles dans une population d'échantillons fécaux de nourrisson. Les résultats démontrent qu'une approche protéomique fournit des changements et des réponses fonctionnelles avec une couverture significativement plus élevée de genres bactériens que l'approche de pyroséquencage. L'analyse des voies révèle également les différences entre les microbiomes individuels et fournit des informations sur leurs réponses fonctionnelles à l'alimentation, la maladie et la thérapie. Cours de courte durée : Développement et déploiement d'une analyse de détection de cytokine intracellulaire dans des essais de thérapie cellulaire adoptive    SC24 « Cytométrie de flux et analyses de cellules phénotypiques en immuno-oncologie » Intervenant : Yoav Peretz, PhD, directeur scientifique, ImmuneCarta Lundi 20 février, 10 h 10 Présentation d'affiche à la conférence « Analyse métaprotéomique du microbiome fécal du nourrisson » Laetitia Cortes[1], Aude Tartière[1], Julie Piquenot[1], Sebastian Tims[2], Joost W. Gouw[2], Jan Knol[2],[3], Harm Wopereis[2],[3] et Daniel Chelsky[1] [1]Caprion Biosciences Inc, Montréal, Canada ; [2]Nutricia Research, Utrecht, Pays-Bas; [3]Université Wageningen, Laboratoire de Microbiologie, Wageningen, Pays-Bas À propos de Caprion Biosciences, Inc. Caprion Biosciences est le principal fournisseur de services de protéomique et de surveillance immunitaire à l'industrie pharmaceutique et de biotechnologie.  Sa division de surveillance immunitaire, ImmuneCarta®, offre des services de cytométrie de flux multiparamétrique exclusive pour les analyses fonctionnelles des réponses immunitaires innées et adaptatives.  La division de protéomique de Caprion, ProteoCarta™, offre une spectrométrie de masse exclusive sans gel et sans marquage pour la mesure comparative complète, quantitative et robuste des protéines dans de grands ensembles d'échantillons biologiques pour la découverte et la validation de biomarqueurs protéiques.  Établie à Montréal, au Canada, Caprion offre des services de protéomique et de surveillance immunitaire à grande échelle à plus de 50 clients majeurs de l'industrie pharmaceutique et de biotechnologie depuis plus de 15 ans. Caprion, une société privée, est détenue en majorité par Global Healthcare Opportunities, ou GHO Capital Partners LLP. Pour en savoir plus, veuillez consulter http://www.caprion.com. Contact pour les médias, Guylaine Galipeau, directrice du marketing, Caprion Biosciences Inc., ggalipeau@caprion.com ,  +1-514-360-3600


Eussen S.,Nutricia Research | Alles M.,Nutricia Research | Uijterschout L.,Haga Hospital | Brus F.,Haga Hospital | Van Der Horst-Graat J.,Nutricia Research
Annals of Nutrition and Metabolism | Year: 2015

Background: Iron deficiency is the most common nutritional disorder in the world. Young children are particularly vulnerable to the consequences of iron deficiency because of their rapidly developing brain. This review evaluates the prevalence of inadequate iron intake and iron deficiency (anaemia) in European children aged 6-36 months. Summary: Computerized searches for relevant articles were performed in November 2013. A total of 7,297 citations were screened and 44 studies conducted in 19 European countries were included in this review. In both infants (6-12 months) and young children (12-36 months), the mean value of iron intakes in most countries was close to the RDA. Nevertheless, proportions of inadequate intakes were considerable, ranging from about 10% in the Netherlands up to 50% in Austria, Finland and the United Kingdom. The prevalence of iron deficiency varied between studies and was influenced by children's characteristics. Two to 25% of infants aged 6-12 months were found to be iron deficient, with a higher prevalence in those who were socially vulnerable and those who were drinking cow's milk as a main type of drink in their first year of life. In children aged 12-36 months, prevalence rates of iron deficiency varied between 3 and 48%. Prevalence of iron deficiency anaemia in both age groups was high in Eastern Europe, as high as 50%, whereas the prevalence in Western Europe was generally below 5%. Key Messages: In most European countries, mean iron intakes of infants and children aged 6 to 36 months were found to be close to the RDA. Nevertheless, high proportions of inadequate intakes and high prevalence rates of iron deficiency were observed. Health programs should (keep) focus(ing) on iron malnutrition by educating parents on food choices for their children with iron-rich and iron-fortified foods, and encourage iron supplementation programmes where iron intakes are the lowest. © 2015 S. Karger AG, Basel.


Bailey R.L.,U.S. National Institutes of Health | Bailey R.L.,Purdue University | van Wijngaarden J.P.,Nutricia Research
Current Osteoporosis Reports | Year: 2015

The risk of osteoporosis and bone fractures increases with age. Several other factors are also related to bone disease including gender, race/ethnicity, physical activity, alcohol, smoking, estrogen, and calcium and vitamin D. B-vitamins (folate, B12, and B6) are also emerging dietary factors related to bone health, both individually and through their action on influencing total plasma homocysteine concentrations (tHcy). The primary objective of this review is to summarize the available data on B-vitamins and bone health, highlighting clinical trials and observational data. In populations without folic acid fortification, the totality of evidence suggests that elevated tHcy has a small but significant association with bone fracture risk and bone quality but not on bone mineral density (BMD) or bone turnover biomarkers. Very little supportive evidence exists for a direct role of folate for either BMD or fracture risk; however, the data available are quite limited. Meta-analyses and some cross-sectional and cohort studies suggest a small but significant role of vitamin B12 status on risk of fracture but not on BMD. The mechanism by which tHcy and B12 may influence bone health is not well characterized but may be through modulation of collagen cross-linking or through altering osteoclasts or osteoblasts. Much more data are needed—particularly the role that each vitamin directly has on bone, or whether the vitamins only exert their effect though tHcy concentrations. Nevertheless, consistent findings across different populations with different study designs suggest a role for tHcy and B12 in reducing fracture risk. © 2015, Springer Science+Business Media New York (outside the USA).


Hogenkamp A.,University Utrecht | Thijssen S.,University Utrecht | van Vlies N.,University Utrecht | van Vlies N.,University of Amsterdam | And 2 more authors.
Journal of Nutrition | Year: 2015

Background: Previously, maternal supplementation with short-chain galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS; ratio 9:1) was shown to affect maternal and fetal immune status in mice. Objective: This study was designed to test the long-term effects of supplementation of mice with scGOS/lcFOS before and during pregnancy on the immune response in the offspring, using an ovalbumin (OVA)-induced model for experimental allergic asthma. Methods: Female Balb/c mice were fed a control diet or a diet supplemented with 3% scGOS/lcFOS and mated to C57BL/6 males. All dams were fed the control diet after delivery. At 6 wk, male offspring received an intraperitoneal injection of aluminum hydroxide and OVA (control and scGOS/lcFOS group) or saline (sham group). The acute allergic skin response (ASR) after intradermal challenge with OVA or saline was measured at 8 wk. After 3 airway challenges with nebulized OVA or saline, lung function was measured. Results: The scGOS/lcFOS group had a significantly lower acute ASR (85 ± 9 μm) than the control group (124 ± 9 μm; P = 0.01). Lower lung resistance from a response to methacholine challenge was seen in the scGOS/lcFOS group. OVA-specific immunoglobulin (Ig)E concentrations in the control group [93 ± 45 arbitrary unit (AU)] and the scGOS/lcFOS group (67 ± 45 AU) were higher than in the sham group (11 ± 2 AU). OVA specific IgG2a concentrations in the scGOS/lcFOS (146 ± 24 AU) were higher than in the sham group (2 ± 0.3 AU) and control group (18 ± 3.5 AU; P < 0.05). Finally, the scGOS/lcFOS group had a higher percentage of regulatory T cells (1.11% ± 0.07%) than the sham group (0.14% ± 0.03%) and the control group (0.11% ± 0.02%; P < 0.05). Conclusion: Maternal supplementation of mice with scGOS/lcFOS during pregnancy leads to a significant decrease in allergic symptoms in the offspring. © 2015 American Society for Nutrition.


Cansev M.,Uludag University | van Wijk N.,Nutricia Research | Turkyilmaz M.,Uludag University | Orhan F.,Uludag University | And 2 more authors.
Neurobiology of Aging | Year: 2015

Fortasyn Connect (FC) is a specific nutrient combination designed to target synaptic dysfunction in Alzheimer's disease by providing neuronal membrane precursors and other supportive nutrients. The aim of the present study was to investigate the effects of FC on hippocampal cholinergic neurotransmission in association with its effects on synaptic membrane formation in aged rats. Eighteen-month-old male Wistar rats were randomized to receive a control diet for 4weeks or an FC-enriched diet for 4 or 6weeks. At the end of the dietary treatments, acetylcholine (ACh) release was investigated by invivo microdialysis in the right hippocampi. On completion of microdialysis studies, the rats were sacrificed, and the left hippocampi were obtained to determine the levels of choline, ACh, membrane phospholipids, synaptic proteins, and choline acetyltransferase. Our results revealed that supplementation with FC diet for 4 or 6weeks, significantly enhanced basal and stimulated hippocampal ACh release and ACh tissue levels, along with levels of phospholipids. Feeding rats the FC diet for 6weeks significantly increased the levels of choline acetyltransferase, the presynaptic marker Synapsin-1, and the postsynaptic marker PSD-95, but decreased levels of Nogo-A, a neurite outgrowth inhibitor. These data show that the FC diet enhances hippocampal cholinergic neurotransmission in aged rats and suggest that this effect is mediated by enhanced synaptic membrane formation. These data provide further insight into cellular and molecular mechanisms by which FC may support memory processes in Alzheimer's disease. © 2015 The Authors.


Scholtens P.A.,Nutricia Research | Goossens D.A.M.,Nutricia Research | Staiano A.,University of Naples
World Journal of Gastroenterology | Year: 2014

Human milk is considered to be the optimal source of infant nutrition. Some of the benefits of breastfeeding have been ascribed to human milk oligosaccharides (HMO). For instance, HMO can affect faecal characteristics such as stool consistency and stool frequency. Such effects on stool characteristics can be beneficial for young infants as hard stools and even constipation is common in that age group. Prebiotics in infant milk formulas have been introduced to exert similar functionalities. A specific mixture of prebiotics consists of a combination of short chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS) in a ratio of 9:1. This specific mixture has been developed to closely resemble the molecular size composition of HMO. Many studies have been done with scGOS/lcFOS, and indicators for digestive comfort have often been included as secondary outcomes. This review summarizes the effects of scGOS/lcFOS (9:1) on stool consistency, stool frequency and transit time in healthy term and preterm infants. In several of the studies with scGOS/lcFOS in a ratio of 9:1 in infant milk formulas, positive effects of this mixture on stool characteristics such as stool consistency and stool frequency were observed. As stool consistency was shown to be correlated to whole gut transit time, scGOS/lcFOS can be hypothesised to have a role in reducing the risk of constipation. © 2014 Baishideng Publishing Group Inc. All rights reserved.


Verreijen A.M.,University of Amsterdam | Verlaan S.,Nutricia Research | Engberink M.F.,University of Amsterdam | Swinkels S.,Nutricia Research | And 2 more authors.
American Journal of Clinical Nutrition | Year: 2015

Background: Intentional weight loss in obese older adults is a risk factor for muscle loss and sarcopenia. Objective: The objective was to examine the effect of a high whey protein-, leucine-, and vitamin D-enriched supplement on muscle mass preservation during intentional weight loss in obese older adults. Design: We included 80 obese older adults in a double-blind randomized controlled trial. During a 13-wk weight loss program, all subjects followed a hypocaloric diet (-600 kcal/d) and performed resistance training 3x/wk. Subjects were randomly allocated to a high whey protein-, leucine-, and vitamin D-enriched supplement including a mix of other macro- and micronutrients (150 kcal, 21 g protein; 10x/wk, intervention group) or an isocaloric control. The primary outcome was change in appendicular muscle mass. The secondary outcomes were body composition, handgrip strength, and physical performance. Data were analyzed by using ANCOVA and mixed linear models with sex and baseline value as covariates. Results: At baseline, mean ± SD age was 63 ± 5.6 y, and body mass index (in kg/m2) was 33 ± 4.4. During the trial, protein intake was 1.11 ± 0.28 g·kg body weight-1·d-1 in the intervention group compared with 0.85 ± 0.24 g·kg body weight-1·d-1 in the control group (P < 0.001). Both intervention and control groups decreased in body weight (-3.4 ± 3.6 kg and -2.8 ± 2.8 kg; both P < 0.001) and fat mass (-3.2 ± 3.1 kg and -2.5 ± 2.4 kg; both P < 0.001), with no differences between groups. The 13-wk change in appendicular muscle mass, however, was different in the intervention and control groups [+0.4 ± 1.2 kg and -0.5 ± 2.1 kg, respectively; β = 0.95 kg (95% CI: 0.09, 1.81); P = 0.03]. Muscle strength and function improved over time without significant differences between groups. Conclusion: A high whey protein-, leucine-, and vitamin D-enriched supplement compared with isocaloric control preserves appendicular muscle mass in obese older adults during a hypocaloric diet and resistance exercise program and might therefore reduce the risk of sarcopenia. This trial was registered at the Dutch Trial Register (http://www.trialregister.nl) as NTR2751. © 2015 American Society for Nutrition.


Van Straaten E.C.W.,VU University Amsterdam | Van Straaten E.C.W.,Nutricia Research | Scheltens P.,VU University Amsterdam | Gouw A.A.,VU University Amsterdam | Stam C.J.,VU University Amsterdam
Alzheimer's Research and Therapy | Year: 2014

Electroencephalography (EEG) is a longstanding technique to measure electrical brain activity and thereby an indirect measure of synaptic activity. Synaptic dysfunction accompanies Alzheimer's disease (AD) and EEG can be regarded as a potentially useful biomarker in this disease. Lately, emerging analysis techniques of time series have become available for EEG, such as functional connectivity and network analysis, which have increased the possibilities for use in AD clinical trials. In this review, we report the EEG changes in the course of AD, including slowing of the EEG oscillations, decreased functional connectivity in the higher-frequency bands, and decline in optimal functional network organization. We discuss the use of EEG in clinical trials and provide directions for future research. © 2014 van Straaten et al.; licensee BioMed Central Ltd.

Loading Nutricia Research collaborators
Loading Nutricia Research collaborators